MaxCyte, Inc. (MXCT)

NASDAQ: MXCT · IEX Real-Time Price · USD
5.86
-0.29 (-4.72%)
Nov 29, 2022 3:59 PM EDT - Market closed
-4.72%
Market Cap 643.63M
Revenue (ttm) 41.99M
Net Income (ttm) -23.64M
Shares Out 101.81M
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 210,406
Open 6.16
Previous Close 6.15
Day's Range 5.84 - 6.16
52-Week Range 3.36 - 11.56
Beta 0.96
Analysts Buy
Price Target 13.94 (+137.9%)
Earnings Date Nov 9, 2022

About MXCT

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. Th... [Read more]

Industry Medical Devices
IPO Date Jul 30, 2021
CEO Douglas Doerfler
Employees 84
Stock Exchange NASDAQ
Ticker Symbol MXCT
Full Company Profile

Financial Performance

In 2021, MaxCyte's revenue was $33.89 million, an increase of 29.52% compared to the previous year's $26.17 million. Losses were -$19.08 million, 61.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for MXCT stock is "Buy." The 12-month stock price forecast is 13.94, which is an increase of 137.88% from the latest price.

Price Target
$13.94
(137.88% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates

MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 33.33% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

MaxCyte Reports Third Quarter 2022 Financial Results

22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022

2 weeks ago - GlobeNewsWire

MaxCyte to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Nov. 02, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,...

3 weeks ago - GlobeNewsWire

MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022

ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance i...

1 month ago - GlobeNewsWire

MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program

Vertex Pharmaceuticals will continue to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support gene-edited cell therapy exa-cel, formerly known as CTX001™ for hemoglobinopathies

2 months ago - GlobeNewsWire

MaxCyte, Inc. (MXCT) Moves 9.3% Higher: Will This Strength Last?

MaxCyte, Inc. (MXCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

2 months ago - Zacks Investment Research

MaxCyte Debuts New State-of-the-Art Headquarters in Maryland's I-270 Biotech Corridor

Expanded facilities illustrate MaxCyte's commitment to Montgomery County and the state of Maryland, building the life sciences community, and propelling local job opportunities.

2 months ago - GlobeNewsWire

MaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance ...

2 months ago - GlobeNewsWire

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates

MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 6.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results

45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022

3 months ago - GlobeNewsWire

MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advanc...

4 months ago - GlobeNewsWire

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance...

6 months ago - GlobeNewsWire

MaxCyte Reports First Quarter Financial Results

MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and ...

6 months ago - GlobeNewsWire

MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022

GAITHERSBURG, Md., April 20, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advan...

7 months ago - GlobeNewsWire

MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2...

GAITHERSBURG, Md., April 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advan...

7 months ago - GlobeNewsWire

MaxCyte Reports Fourth Quarter and Full Year Financial Results

MaxCyte Provides Initial 2022 Guidance MaxCyte Provides Initial 2022 Guidance

8 months ago - GlobeNewsWire

MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer

Dr. Sumen brings extensive experience in scientific and technology evaluation, process development and leadership. Dr. Sumen brings extensive experience in scientific and technology evaluation, process ...

8 months ago - GlobeNewsWire

MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022

GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to...

9 months ago - GlobeNewsWire

MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs

Intima Bioscience to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its solid tumor cell-therapy candidates Intima Bioscience to use MaxCyte's Flow ...

9 months ago - GlobeNewsWire

MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results

GAITHERSBURG, Md., Jan. 23, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to ...

10 months ago - GlobeNewsWire

MaxCyte Reports Third Quarter Financial Results

GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to ...

1 year ago - GlobeNewsWire

MaxCyte Board Member Richard Douglas, PhD, Appointed Chairman of the Board

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on providing enabling platform technologies t...

1 year ago - GlobeNewsWire

Result of AGM

GAITHERSBURG, Md., Oct. 29, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to ...

1 year ago - GlobeNewsWire

MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs

Nkarta to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its oncology cell-therapy candidates Nkarta to use MaxCyte's Flow Electroporation® technolo...

1 year ago - GlobeNewsWire

MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021

GAITHERSBURG, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to ...

1 year ago - GlobeNewsWire